Drug Profile
CB 988
Alternative Names: CB-988Latest Information Update: 28 May 2021
Price :
$50
*
At a glance
- Originator Carna Biosciences
- Class Small molecules
- Mechanism of Action Agammaglobulinaemia tyrosine kinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Haematological malignancies
Most Recent Events
- 28 May 2021 No recent reports of development identified for research development in Haematological-malignancies in Japan
- 01 Apr 2017 Early research in Haematological malignancies in Japan
- 01 Apr 2017 Pharmacodynamics data from a preclinical trial in Haematological malignancies presented at the 108th Annual Meeting of the American Association for Cancer Research (AACR-2017)